How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events (Q38062039)

28 August 2017

1 reference

title

How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events (English)

1 reference

28 August 2017

author name string

María-Victoria Mateos

series ordinal

1

1 reference

28 August 2017

language of work or name

1 reference

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

36 Suppl 1

1 reference

28 August 2017

page(s)

S35-43

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Management of treatment-related adverse events in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Management of disease- and treatment-related complications in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Chemotherapy-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Multiple myeloma, painful neuropathy, acupuncture?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970007-3

7 January 2021

10.1016/S0145-2126(12)70007-3

Identifiers

DOI

1 reference

28 August 2017

1 reference